OBI-221 / OBI Pharma - LARVOL DELTA

The MET/HER3 antibody-drug conjugate with dual payload: A dual-target approach to eliminate tumor escape mechanism (AACR 2026) - "Broad activity was observed in c-MET/HER3 dual-positive non-small cell lung cancer and colorectal cancer models. This glycan-based site specific MET/HER3 bispecific dual-payload ADC warrants further clinical investigation as a promising therapeutic option for refractory tumors co-expressing cMET and HER3."

ADC • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • ERBB3 • MET

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies (ACN Newswire) - "Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ADC enabling technologies(GlycOBI and GlycOBI DUO."

Preclinical • Oncology